Details for Patent: 9,890,141
✉ Email this page to a colleague
Title: | Crystalline pharmaceutical and methods of preparation and use thereof |
Abstract: | Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention. ##STR00001## |
Inventor(s): | Burnier; John (Pacifica, CA) |
Assignee: | SARCODE BIOSCIENCE INC. (Brisbane, CA) |
Filing Date: | May 03, 2016 |
Application Number: | 15/144,892 |
Claims: | 1. A composition comprising an isolated compound of Formula I: ##STR00020## wherein said compound is synthesized according to a method comprising the steps: performing hydrolysis of Formula AA with a base: ##STR00021## wherein R is a carbon containing moiety; and isolating the compound of Formula I, wherein the hydrolysis is performed in a solution comprising acetone, the composition is essentially free of a chemical catalyst, and the compound of Formula I is isolated by way of recrystallization from a solution comprising acetone. 2. The composition of claim 1, wherein R is a substituted or unsubstituted group selected from lower alkyl, lower alkenyl, lower alkynyl, cyclo(lower)alkyl, cyclo(lower)alkenyl, aryl, aralkyl, heterocyclyl, and heteroaryl groups. 3. The composition of claim 1, wherein R is benzyl. 4. The composition of claim 1, wherein the base is sodium hydroxide. |